|
Join the Millions Who Have Become Nonsmokers Using the Easyway Method
On September 2006, Pfizer issued a press release announcing European Commission approval
of Champix, its new quit smoking pill.
It boasts that "after one year,
approximately one-in-five patients who received the 12-week course of varenicline [Champix] remained smoke-free."
Smoking is a chronic relapsing medical condition that typically
involves a physical and psychological addiction to nicotine.
In Europe alone, more than 1.2 million people die each year from
smoking- related diseases.
In addition to the human toll, there is a significant social and economic cost associated with
smoking.
By 2010, the World Health Organization predicts the annual global cost of tobacco-related illness will be approximately
$500 billion, with Europe accounting for up to $165 billion of this sum.
How Champix works?
|